Innovative antibody discovery may lead to new treatment for Parkinson’s disease
Cambridge-based Alchemab Therapeutics has won a large grant from the Michael J. Fox Foundation to advance research into Parkinson’s disease (PD).
The $595,000 grant will support Alchemab’s research into antibodies that target prostaglandin biology, a potentially transformative new approach to the treatment of Parkinson’s disease.
Alchemab’s research focuses on antibodies isolated from individuals that demonstrate resistance to Parkinson’s disease. The company’s cutting-edge platform combines proteomics, bioinformatics and machine learning to identify targets that may contribute to disease resistance.
This study delves into the role that the prostaglandin pathway plays in disease progression and points to potential new therapeutic approaches.
The grant is part of MJFF’s Parkinson’s Treatment Pipeline Program, which aims to accelerate the development of treatments that meet the unmet medical needs of people with Parkinson’s disease.
The program’s goal is to fund research that can prevent, stop or slow the progression of the disease or relieve everyday symptoms.
Young Kwon, CEO of Archemab, was enthusiastic about the collaboration, saying, “We are pleased to work with the Michael J. Fox Foundation. This exciting program is another example of the power of a patient-led, unbiased approach to target and treatment discovery.”
Sohini Choudhury, chief program officer at MJFF, added: “Archemab takes a unique research approach and we hope this research will open up new treatment pathways and bring hope to patients suffering from this disease.”
Alchemab’s innovative approach, supported by MJFF, could lead to major advances in the understanding of PD and the development of targeted therapies, bringing new hope to patients and their families.
